Aerovate Therapeutics, Inc.
INHALABLE FORMULATIONS FOR KINASE INHIBITION
Last updated:
Abstract:
The invention relates to inhalable formulations configured to inhibit target combinations of kinases for the treatment of cardiovascular and pulmonary diseases such as pulmonary arterial hypertension (PAH).
Status:
Application
Type:
Utility
Filling date:
14 May 2020
Issue date:
19 Nov 2020